SELLAS: AML Platform Adds Depth, But REGAL Binary Still Drives

What happened

A new Seeking Alpha article highlights SELLAS Life Sciences' dual-path AML franchise, noting that GPS (Phase 3 REGAL) and SLS009 (CDK9 inhibitor) together create a platform story beyond the imminent REGAL OS readout. The company's cash position has strengthened to ~$135.8 million via warrant exercises, extending runway into 2027 and reducing immediate financing pressure. However, the DeepValue master report maintains a WAIT rating, emphasizing that the stock remains a binary event-driven name where REGAL topline (triggered at 80 deaths, currently at 78) and ATM dilution risk dominate. The article's platform framing adds optionality, but the core investment thesis still hinges on REGAL OS results and management's capital allocation discipline ahead of data.

Implication

The new article bolsters the long-term thesis by suggesting SLS009 could provide a second value driver post-REGAL, but the near-term setup remains binary. Wait for the event trigger (80 deaths) and a clean AT M-free balance sheet to reduce uncertainty. If REGAL OS is positive and dilution is avoided, the platform story justifies a higher valuation (bull case $14). If not, the $3.50 bear case materializes quickly. Maintain sizing discipline until those two checkpoints are met.

Thesis delta

The article's platform narrative slightly increases the probability of a positive long-term outcome by reducing reliance on REGAL alone, but it does not change the immediate risk/reward. The WAIT rating remains intact because the binary trigger and ATM overhang still dominate the next 6 months. The thesis now includes a modest tailwind from SLS009 optionality, but the delta is marginal—the stock still needs a clean REGAL readout to unlock value.